In this Cannabis & Tech Today column, Scott Mazza, co-founder of Vitality CBD, argues that the future of hemp regulation under the Farm Bill 2025 must be guided by scientific evidence rather than political reaction. Drawing on industry experience, Mazza outlines how research increasingly supports CBD’s role in areas such as anxiety, sleep, and pain management, while warning that regulatory uncertainty and state-level bans undermine consumer trust and responsible operators. He calls for nuanced, science-based federal standards, focused on testing, labeling, and access, to protect consumers without reversing the progress made since hemp legalization, as published in Cannabis & Tech Today.

In an article for Cannabis & Tech Today, Scott Mazza argues that reclassifying cannabis from Schedule I to Schedule III would mark a pivotal shift in U.S. drug policy by reducing stigma, expanding access to scientific research, and aligning federal law with current medical evidence and public opinion. He highlights how rescheduling would ease restrictions on clinical trials, accelerate innovation in areas such as pain management and mental health, and improve access to banking and capital for cannabis businesses. Mazza concludes that grounding cannabis policy in data and science could deliver broad societal, economic, and research benefits while creating a more equitable regulatory environment for the industry.